HIV Seropositivity

264  relevant articles (4 outcomes, 27 trials/studies) found for this Disease

AIDS Seroconversions; AIDS Seropositivities; Anti HIV Positivity; Anti-HIV Positivities; Antibody Positivities, HIV; Antibody Positivity, HIV; HIV Antibody Positivities; HIV Seroconversions; HIV Seropositivities; HTLV III Seroconversion; HTLV III Seropositivity; HTLV-III Seroconversions; HTLV-III Seropositivities; Positivities, Anti-HIV; Positivities, HIV Antibody; Positivity, Anti-HIV; Positivity, HIV Antibody; Seroconversion, AIDS; Seroconversion, HIV; Seroconversion, HTLV-III; Seroconversions, AIDS; Seroconversions, HIV; Seroconversions, HTLV-III; Seropositivities, AIDS; Seropositivities, HIV; Seropositivities, HTLV-III; Seropositivity, AIDS; Seropositivity, HIV; Seropositivity, HTLV-III; AIDS Seroconversion; AIDS Seropositivity; Anti-HIV Positivity; HIV Antibody Positivity; HIV Seroconversion; HTLV-III Seroconversion; HTLV-III Seropositivity

Relationship Network

Disease Context: Research Results

Related Diseases

1.	Retinitis
2.	HIV Infections (HIV Infection)
3.	Acquired Immunodeficiency Syndrome (AIDS)
4.	Infection
5.	Needlestick Injuries (Needlestick Injury)

Experts

1.	CASCADE Collaboration: 2 articles (01/2006 - 10/2002)
2.	Dorrucci, M: 2 articles (04/2005 - 01/2004)
3.	Rezza, G: 2 articles (04/2005 - 01/2004)
4.	Iacobelli, S: 2 articles (04/2005 - 01/2004)
5.	Weber, Bernard: 2 articles (04/2003 - 11/2002)
6.	van Zijl, A: 1 article (10/2008)
7.	Scott, L: 1 article (10/2008)
8.	du Plessis, N: 1 article (10/2008)
9.	Mhlongo, S: 1 article (10/2008)
10.	Radebe, F: 1 article (10/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to HIV Seropositivity:

1.	AntigensIBA 06/01/1991 - "Antibody titers to EBV viral capsid antigen did not differ between cases and controls prior to the time of seroconversion to HIV but were significantly increased among cases by the first seropositive study visit and remained elevated during the 18 months after HIV seroconversion" 01/01/2004 - "For 22 selected, commercial HIV seroconversion panels, the mean time of detection with the combined-format HIV antigen-antibody assay was reduced by 6.15 days compared to that with a similar third-generation single-format HIV antibody assay" 04/11/2003 - "HIV seroconversion: performance of combined antigen/antibody assays." 11/01/2002 - "Human immunodeficiency virus (HIV) antigen-antibody combination assays: evaluation of HIV seroconversion sensitivity and subtype detection." 09/01/2001 - "All assays were evaluated for the ability to detect p24 antigen from HIV-1 groups M and O, antibody-positive plasma samples from HIV-1 groups M and O, HIV-2, and 19 HIV seroconversion panels" Order ALL the reference details at left...
2.	HIV AntibodiesIBA 09/01/1992 - "Surveillance of human immunodeficiency virus (HIV) antibodies in medicolegal autopsies in Finland--monitoring early changes in HIV-seropositivity among risk groups and average population." 11/18/1989 - "The need for reliable epidemiological data on HIV seropositivity rates in a general population appears to conflict with the ethical requirement that consent be obtained from persons whose blood is screened for HIV antibodies" 12/01/1987 - "HIV antibodies in a remote rural area in Rwanda, Central Africa: an analysis of potential risk factors for HIV seropositivity." 05/01/1988 - "Ninety percent of the 264 drug addicts (mean age 26 +/- 0.8 years) were found to have HIV antibodies and there was a significant increase (P less than 0.01) in the frequency of HIV antibody positivity with increasing duration of exposure to parenteral drug abuse" 01/01/2004 - "A significant reduction in the HIV seroconversion window was achieved by combining detection of HIV antibodies and antigen into a single assay format" Order ALL the reference details at left...
3.	Ganciclovir (Cytovene)FDA LinkGeneric 05/01/1994 - "Age, sex, risk factors, the time interval between HIV seropositivity to CMV disease were examined, as well as efficacy of gancyclovir therapy in both groups of patients with symptomatic and asymptomatic retinitis" Order ALL the reference details at left...
4.	RNA (Ribonucleic Acid)IBA 08/15/1994 - "The purpose of this study was to quantitate hepatitis C virus (HCV) RNA levels in serial samples from HIV-seropositive (HIV+) and HIV-seronegative (HIV-) hemophiliacs before and after HIV seroconversion, and to examine the relationship of HCV RNA levels to CD4 cell counts and to hepatic dysfunction over time" 04/01/2006 - "Older age (P < 0.001), HIV seropositivity (P = 0.03), and HCV nongenotype 1 (P = 0.05) were predictors of higher HCV RNA levels on multivariate analysis" 05/01/2005 - "METHODS: In the French Agence Nationale de Recherches sur le SIDA SEROCO cohort, 426 patients with HIV seroconversion (i.e., seroconverters) enrolled between 1988 and 1995 had serial measurement of HIV RNA levels during follow-up (with a cutoff date of 31 December 2002)" 10/01/2003 - "Prediction of incident neurocognitive impairment by plasma HIV RNA and CD4 levels early after HIV seroconversion." 08/15/2002 - "HCV RNA load stabilized at 4 years after HIV seroconversion, and this point was used for analysis" Order ALL the reference details at left...
5.	Cocaine (Cocaine HCl)IBA 01/01/2002 - "This study examines the influence of HIV-seropositivity and antiviral medications on cerebral blood flow in cocaine abusers" 07/01/1994 - "To examine the putative protective effect of disinfectant use on HIV seroconversion among injecting drug users, we conducted a nested case-control study of black heterosexuals comparing 34 HIV seroconverters with 154 persistent seronegatives matched on gender, cocaine injection (yes/no), date of study entry, and duration of follow-up" 11/01/1991 - "To examine the putative protective effect of disinfectant use on HIV seroconversion among intravenous drug users, we conducted a nested case-control study comparing 22 black heterosexual HIV seroconverters with 95 persistent seronegatives matched on gender, use of cocaine, date of study entry, and duration of follow-up" 06/28/2006 - "Factors independently associated with shorter time to injection relapse were male gender, homelessness, HIV seropositivity, use of alcohol, cigarettes, non-injection cocaine, sexual abstinence and having a longer time to the first cessation" 09/01/2005 - "In an adjusted model controlling for potential confounding variables, being aboriginal (relative hazard [RH] = 1.68, 95% CI: 1.15-2.48), injecting cocaine daily (RH = 2.71, 95% CI: 1.87-3.95), and requiring help injecting (RH = 1.79, 95% CI: 1.23-2.62) remained independent predictors of HIV seroconversion" Order ALL the reference details at left...
6.	Zidovudine (Retrovir)FDA LinkGeneric 09/01/1999 - "Assuming that 35% of exposures were to HIV-positive sources, the zidovudine regimen prevented 53 HIV seroconversions per 100,000 exposures, at a societal cost of $2.0 million per case of HIV prevented" 03/01/1994 - "No seropositive men were observed among those who were aware of the woman's HIV seropositivity since the beginning of the relationship or were partners of a zidovudine-treated woman" 06/12/1993 - "HIV seroconversion after occupational exposure despite early prophylactic zidovudine therapy." 04/24/1993 - "HIV seroconversion after occupational exposure despite early prophylactic zidovudine therapy." 10/01/2000 - "A study of health care workers suggests that zidovudine taken after needlestick injuries can dramatically reduce HIV seroconversion" Order ALL the reference details at left...
7.	Indinavir (Crixivan)FDA Link 06/01/2002 - "In multivariate analysis, the development of the mixed lipodystrophy syndrome was associated with a longer use of indinavir (OR=1.03, 95% CI: 1.00-1.06), ritonavir (OR=1.06, 1.02-1.09) and stavudine (OR=1.05, 1.02-1.08) and also with age, a longer duration of HIV seropositivity and an advanced stage of HIV infection" 01/01/2003 - "SEARCH STRATEGY: The following electronic databases were searched for relevant randomized trials or reviews: 1. MEDLINE for the years 1982-May 2003 using the search terms human immunodeficiency virus, antiretroviral therapy, maintenance therapy, zidovudine, lamivudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, AIDS, anti-HIV agents, HIV infection and HIV seropositivity" 01/01/2000 - "SEARCH STRATEGY: The following electronic databases were searched for relevant randomized trials or reviews: 1. MEDLINE for the years 1982-1999 using the search terms human immunodeficiency virus, antiretroviral therapy, maintenance therapy, zidovudine, lamivudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, AIDS, anti-HIV agents, HIV infection and HIV seropositivity 2. AIDSLINE for the years 1982-1999 using the search terms antiretroviral therapy, maintenance therapy, zidovudine, lamidvudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, anti-HIV agents 3. The Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effectiveness and the Cochrane Clinical Trials Register in the Cochrane Library, Issue 2, 1999" Order ALL the reference details at left...
8.	Anti-HIV Agents (AIDS Drugs)IBA 12/31/1991 - "It contains information obtained by 31 December 1990 from 31 countries under the headings: illegal use of drugs; AIDS among intravenous drug users; HIV seropositivity among drug users; measures to prevent HIV infection among drug users; training programmes for drug workers." 01/01/2003 - "SEARCH STRATEGY: The following electronic databases were searched for relevant randomized trials or reviews: 1. MEDLINE for the years 1982-May 2003 using the search terms human immunodeficiency virus, antiretroviral therapy, maintenance therapy, zidovudine, lamivudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, AIDS, anti-HIV agents, HIV infection and HIV seropositivity" 01/01/2000 - "SEARCH STRATEGY: The following electronic databases were searched for relevant randomized trials or reviews: 1. MEDLINE for the years 1982-1999 using the search terms human immunodeficiency virus, antiretroviral therapy, maintenance therapy, zidovudine, lamivudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, AIDS, anti-HIV agents, HIV infection and HIV seropositivity 2. AIDSLINE for the years 1982-1999 using the search terms antiretroviral therapy, maintenance therapy, zidovudine, lamidvudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, anti-HIV agents 3. The Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effectiveness and the Cochrane Clinical Trials Register in the Cochrane Library, Issue 2, 1999" Order ALL the reference details at left...
9.	Stavudine (Zerit)FDA Link 06/01/2002 - "In multivariate analysis, the development of the mixed lipodystrophy syndrome was associated with a longer use of indinavir (OR=1.03, 95% CI: 1.00-1.06), ritonavir (OR=1.06, 1.02-1.09) and stavudine (OR=1.05, 1.02-1.08) and also with age, a longer duration of HIV seropositivity and an advanced stage of HIV infection" 01/01/2003 - "SEARCH STRATEGY: The following electronic databases were searched for relevant randomized trials or reviews: 1. MEDLINE for the years 1982-May 2003 using the search terms human immunodeficiency virus, antiretroviral therapy, maintenance therapy, zidovudine, lamivudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, AIDS, anti-HIV agents, HIV infection and HIV seropositivity" 01/01/2000 - "SEARCH STRATEGY: The following electronic databases were searched for relevant randomized trials or reviews: 1. MEDLINE for the years 1982-1999 using the search terms human immunodeficiency virus, antiretroviral therapy, maintenance therapy, zidovudine, lamivudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, AIDS, anti-HIV agents, HIV infection and HIV seropositivity 2. AIDSLINE for the years 1982-1999 using the search terms antiretroviral therapy, maintenance therapy, zidovudine, lamidvudine, indinavir, stavudine, saquinivir, nelfinavir, didanosine, zalcitabine, ritonovir, anti-HIV agents 3. The Cochrane Database of Systematic Reviews, Database of Abstracts of Reviews of Effectiveness and the Cochrane Clinical Trials Register in the Cochrane Library, Issue 2, 1999" Order ALL the reference details at left...
10.	Nonoxynol (Nonoxynol 9)FDA Link 04/01/1994 - "Among spermicides the nonoxynol-9 sponge slightly increased HIV seroconversion in 139 sex workers in Nairobi in a 1992 study" 11/27/1993 - "Lower doses of nonoxynol-9 had a protective effect against HIV seroconversion in studies in Cameroon and Zambia" 11/27/1993 - "A study in Nairobi suggests that use of a sponge impregnated with high dose nonoxynol-9 increased the probability of HIV seroconversion" 07/22/1992 - "The hazard ratio for the association between nonoxynol 9 sponge use and HIV seroconversion was 1.7 (95% confidence interval [CI], 0.9 to 3.0)" Order ALL the reference details at left...

Therapies and Procedures

1.	Condoms (Condom) 05/01/1997 - "A reexamination of HIV seroconversion studies suggests that condoms are 90 to 95% effective when used consistently, i.e" 01/01/1995 - "Decreasing compliance with safe sex guidelines (as measured by numbers of casual partners, participation in anal intercourse and use of condoms) was associated with HIV seropositivity, increased age, and increased participation in sex work; having a regular male partner was not protective against unsafe sexual behaviour, no matter the length of the relationship" 09/01/1992 - "IVDUs who were 1) unmarried, 2) enrolled in the study after 1986, 3) partners of not at-risk individuals, 4) partners of a foreigner and, 5) aware of their partners HIV seropositivity showed significantly higher, albeit still low, frequencies of condom use with steady partners" 04/01/2005 - "Inconsistent condom use during client sex (adjusted hazard ratio [AHR] = 6.7), during oral sex (AHR = 5.6), and at the last sexual encounter (AHR = 7.8), and use of marihuana (AHR = 5.4) were marginally associated with HIV seroconversion" 03/28/2003 - "Over 20% reported willingness to use the Reality condom in the future with a partner of unknown HIV status; willingness was associated with past problems with male condoms and no problems with Reality condoms among receptive partners, and with past use of Reality condoms and HIV seropositivity among insertive partners" Order ALL the reference details at left...
2.	Highly Active Antiretroviral Therapy (HAART) 11/01/2007 - "Time from HIV seroconversion to death: a collaborative analysis of eight studies in six low and middle-income countries before highly active antiretroviral therapy." 09/01/2008 - "We examined the effect of age at HIV seroconversion on response to HAART" 09/01/2008 - "Increasing age at HIV seroconversion from 18 to 40 years is associated with favorable virologic and immunologic responses to HAART." 01/02/2008 - "CONCLUSIONS: Survival following HIV seroconversion has continued to improve over calendar time in our cohort, even in the more recent years of HAART availability" 01/02/2008 - "OBJECTIVES: To estimate changes over calendar time in survival following HIV seroconversion in the era of HAART and to provide updated survival estimates" Order ALL the reference details at left...
3.	Male Circumcision (Circumcision) 07/01/1994 - "Furthermore, some studies have shown that the distribution of HIV seroprevalence in Africa is closely associated with the geographical pattern of circumcision practices, whilst other workers have shown an association between absence of circumcision and HIV seropositivity" 05/01/2005 - "On multi-variable analysis using time-dependent covariates, independent risk factors for HIV seroconversion were increased number of reported HIV-negative male sex partners (adjusted odds ratio (AOR) = 1.14 per partner, population attributable risk (PAR) = 28%), nitrite inhalant use (AOR = 2.2, PAR = 28%), unprotected receptive anal sex with an HIV unknown serostatus partner (AOR = 2.7, PAR = 15%) or HIV-positive partner (AOR = 3.4, PAR = 12%), protected receptive anal sex with an HIV-positive partner (AOR = 2.2, PAR = 11%), lack of circumcision (AOR = 2.0, PAR = 10%), and receptive oral sex to ejaculation with an HIV-positive partner (AOR = 3.8, PAR = 7%)" 05/01/2005 - "Sexual risk, nitrite inhalant use, and lack of circumcision associated with HIV seroconversion in men who have sex with men in the United States." Order ALL the reference details at left...
4.	Ambulatory Care (Outpatient Care) 10/01/1997 - "Subjects were participants in the Italian Seroconverters Study, a seroincident cohort of more than 1,200 adults seen at ambulatory care clinics in Italy, with observed HIV seroconversion in 1980-1988" 04/01/2001 - "Patients frequently visit ambulatory care settings with acute human immunodeficiency virus (HIV) seroconversion illness, but the illness is often misdiagnosed" Order ALL the reference details at left...
5.	Blood Transfusion (Blood Transfusions) 04/15/2005 - "Despite precautions taken to guarantee blood safety, in the National Blood Transfusion Center (CNTS) of Abidjan, about 30 regular blood donors are detected with HIV seroconversion each year, two-thirds of them men" 09/01/1998 - "A four fold increased risk of HIV seropositivity was also observed among female subjects with a history of blood transfusion in the previous 10 years compared to having received none, the Odds ratio was 4.1 (95% CI = 1.5, 11.1)" 04/01/1993 - "HIV seroconversion in a young child following a single blood transfusion." 09/01/1990 - "Other significant risk factors for HIV seroconversion included: history of genital ulceration after delivery (relative risk, 15.51), use of a cloth to remove vaginal secretions during intercourse (dry sex) (relative risk, 37.95), and blood transfusion (relative risk, 10.89)" 01/01/1988 - "Blood transfusions will become unavailable because no one will want to be tested for HIV seropositivity" Order ALL the reference details at left...